TG Therapeutics, Inc. (TGTX)
53.27
-0.70
(-1.30%)
USD |
NASDAQ |
Oct 19, 13:59
TG Therapeutics Cash from Operations (Annual) : -24.77M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -24.77M |
| December 31, 2024 | -40.52M |
| December 31, 2023 | -31.41M |
| December 31, 2022 | -176.17M |
| December 31, 2021 | -295.63M |
| December 31, 2020 | -214.51M |
| December 31, 2019 | -132.81M |
| December 31, 2018 | -128.92M |
| December 31, 2017 | -93.76M |
| December 31, 2016 | -61.59M |
| December 31, 2015 | -44.69M |
| December 31, 2014 | -35.06M |
| December 31, 2013 | -10.82M |
| December 31, 2012 | -5.188M |
| Date | Value |
|---|---|
| December 31, 2011 | -0.0866M |
| December 31, 2010 | -1.970M |
| December 31, 2009 | -1.050M |
| December 31, 2008 | -4.444M |
| December 31, 2007 | -10.23M |
| December 31, 2006 | -7.751M |
| December 31, 2005 | -6.245M |
| December 31, 2004 | -5.690M |
| December 31, 2003 | -3.452M |
| December 31, 2002 | -1.433M |
| December 31, 2001 | -4.474M |
| December 31, 2000 | -1.153M |
| December 31, 1999 | -2.305M |
| December 31, 1998 | -2.588M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Krystal Biotech, Inc. | 200.86M |
| Vertex Pharmaceuticals, Inc. | 3.631B |
| SELLAS Life Sciences Group, Inc. | -28.39M |
| Travere Therapeutics, Inc. | 37.78M |
| Alnylam Pharmaceuticals, Inc. | 524.08M |